CrossAssetDataThe Company File
···
ITGR

Integer Holdings Corporation

Integer Holdings Corporation is classed by the SEC under Electromedical & Electrotherapeutic Apparatus (industry code 3845), based in Plano, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $1.9 billion and a profit of $103 million (its filed statements).

Product business Electromedical & Electrotherapeutic Apparatus Plano, TX filings since 2000 9 of 9 filed
Ask the desk about ITGR → Compare ITGR with LIVN → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ITGR →

Sector peers: LIVNCNMDTMDXINMD

5.5/10headline grade
vs its business-model standard
6.5/10past 6.3/10present 3.3/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3845, Electromedical & Electrotherapeutic Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.5 out of ten, 9 of 9 metrics filed: past 6.5 out of ten, present 6.3 out of ten, future 3.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2017. 80th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.7 out of ten. +6.2% a year over 10 filed years; profitable in 10 of 10. 57th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 5.8 out of ten. Share count grew 2.2% a year. 9% of cash flow returned. Insiders: 5 sales, 4 purchases. 58th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 5.8 out of ten. ROE 6%: 6¢ of profit per shareholder dollar. Leverage 49%: owes 49¢ per asset dollar. 58th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.6 out of ten. top 24% of 24 in its family; net margin 5.5%. 76th percentile among 24 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.5 out of ten. top 45% of 19 in its family for leadership; chief executive since 2025. 55th percentile among 19 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 2.1 out of ten. bottom 21% of 23 in its family for room to expand. 21st percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 4.9 out of ten. bottom 49% of 25 in its family for growth drivers. 49th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.4 out of ten. bottom 34% of 20 in its family for expectations against reality. 34th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-23 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-07-03 (on EDGAR). Newest results release: Form 8-K filed 2026-08-03 (on EDGAR). Newest filing: Form 8-K, 2026-10-02. Filings on record since 2000. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Cardio and Vascular 60%, Cardiac Rhythm Management Neuromodulation 36%, Other Markets 4%. By geography: United States 53%, Rest of world 25%, Costa Rica 9%, Puerto Rico 7%, Ireland 5%. As tagged in its annual report (Form 10-K, filed 2026-02-23).

Who runs it

Khales, Payman (President & CEO); Senn, Andrew (President, Growth & Innovation); Harris, John A (President, Glob Ops & Manu Tec); Stephens, Jim (President, CRM & Neuro); Thor, Kirk K (Chief Human Resources Officer); Smith, Diron (EVP, Chief Financial Officer); Metcalf, Milo Stephen II (US - EVP, Operations); Thomas, Tommy P (VP, Corporate Controller); Blackwood, Lindsay K. (SVP, Gen Counsel & Secretary); Carr, Terence (EVP, Qlty & Regulatory Affairs); and 11 more. 21 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.